Rein Therapeutics, Inc. Purchase Obligation
Rein Therapeutics, Inc. (RNTX) had Purchase Obligation of $2.34 million as of 2024-03-31, per its 10-Q filed 2024-05-15.
Discontinued › Notes › Commitment and Contingencies
us-gaap:PurchaseObligation · last filed 2024-05-15
- 2024-03-31: Purchase Obligation $2.34M.
- 2023-12-31: Purchase Obligation $2.31M.
| Period end | Purchase Obligation |
|---|---|
| 2024-03-31 | $2.34M 10-Q · filed 2024-05-15 |
| 2023-12-31 | $2.31M 10-K · filed 2024-04-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |